Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
NICE says NHS should fund Novartis’ £1.79m SMA gene therapyThe NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has Share XNICE says NHS should fund Novartis’ £1.79m SMA gene therapyhttps://pharmaphorum.com/news/nice-says-nhs-should-fund-novartis-1-79m-sma-gene-therapy/
Novartis’ bid to expand use of SMA gene therapy delayed after FDA trial requestAnalysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal Share XNovartis’ bid to expand use of SMA gene therapy delayed after FDA trial requesthttps://pharmaphorum.com/news/novartis-bid-to-expand-use-of-sma-gene-therapy-delayed-after-fda-trial-request/
Roche takes on pricey rivals as FDA approves SMA drugRoche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) Share XRoche takes on pricey rivals as FDA approves SMA drughttps://pharmaphorum.com/news/roche-takes-on-pricey-rivals-as-fda-approves-sma-drug/
Biogen plans trial of Spinraza in patients not responding to SMA gene therapyBiogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded Share XBiogen plans trial of Spinraza in patients not responding to SMA gene therapyhttps://pharmaphorum.com/news/biogen-trialling-spinraza-in-patients-not-responding-to-novartis-sma-gene-therapy/
Pandemic hits sales at Novartis after strong launch for SMA gene therapyThe COVID-19 pandemic has bit into sales at Novartis, the big Swiss pharma said in second quarter results, Share XPandemic hits sales at Novartis after strong launch for SMA gene therapyhttps://pharmaphorum.com/news/pandemic-hits-sales-at-novartis-after-strong-launch-for-gene-therapy/
Germany first in EU to get Novartis’ SMA gene therapy, costing almost 2m eurosNovartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced Share XGermany first in EU to get Novartis’ SMA gene therapy, costing almost 2m euroshttps://pharmaphorum.com/news/novartis-eyes-smart-deal-for-sma-gene-therapy-in-uk/
Novartis offers reimbursement options as EU backs costly SMA therapyNovartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare Share XNovartis offers reimbursement options as EU backs costly SMA therapyhttps://pharmaphorum.com/news/novartis-reimbursement-options-as-eu-approves-ultra-pricey-sma-drug/
Novartis publishes long-term data from SMA gene therapyNovartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting Share XNovartis publishes long-term data from SMA gene therapyhttps://pharmaphorum.com/news/novartis-publishes-long-term-data-from-sma-gene-therapy/
